Anaplastic large cell lymphoma: Pathological, molecular and clinical features

British Journal of Haematology

Volumn 114, Issue 4, 2001, Pages 741-760

  Falini, B ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

Author keywords

ALK protein; Anaplastic large cell lymphoma; Fusion proteins; Immunohistochemistry; NPM protein

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; CD30 ANTIGEN; CHIMERIC PROTEIN; MONOCLONAL ANTIBODY; NUCLEOPHOSMIN; PROTEIN TYROSINE KINASE;

AGE; CANCER STAGING; CANCER TISSUE; CHROMOSOME TRANSLOCATION; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; HISTOLOGY; HODGKIN DISEASE; HUMAN; IMMUNOCYTOCHEMISTRY; IMMUNOPHENOTYPING; LARGE CELL LYMPHOMA; LYMPHOMATOID PAPULOSIS; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; REVIEW; SKIN LYMPHOMA; T CELL LYMPHOMA; TUMOR CELL;

ANTIGENS, CD30; CELL NUCLEUS; CELL TRANSFORMATION, NEOPLASTIC; CHROMOSOMES, HUMAN, PAIR 2; CHROMOSOMES, HUMAN, PAIR 5; CYTOPLASM; HUMANS; IMMUNOPHENOTYPING; LYMPHOMA, LARGE-CELL, KI-1; NUCLEAR PROTEINS; PROTEIN-TYROSINE KINASES; TRANSLOCATION, GENETIC;

EID: 0034796741     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2001.02896.x     Document Type: Review

References (173)

1. Nucleolar targeting signal of Rex protein of human T-cell leukemia virus type I specifically binds to nucleolar shuttle protein B-23
2. Ki-1 positive large cell lymphoma. A morphologic and immunologic study of 19 cases
3. Transformation of follicular lymphoma into CD30-large cell lymphoma with anaplastic cytologic features
4. Nucleophosmin-anaplastic lymphoma kinase of large-cell anaplastic lymphoma is a constitutively active tyrosine kinase that utilizes phospholipase C-gamma to mediate its mitogenicity
5. Nucleophosmin-anaplastic lymphoma kinase associated with anaplastic large-cell lymphoma activates the phosphatidylinositol 3-kinase/Akt antiapoptotic signaling pathway
6. Leukaemic presentation of small cell variant anaplastic large cell lymphoma: Report of four cases
7. Structure and functional relationships in human pur H
8. Prognostic significance of CD30 (Ki-1/Ber-H2) expression in primary cutaneous large-cell lymphomas of T-cell origin. A clinicopathologic and immunohistochemical study in 20 patients
9. ALK-positive lymphoma: A single disease with a broad spectrum of morphology
10. Malignant histiocytosis: A specific t (2;5) (p23;q35) translocation? Review of the literature
11. Characterization of t (2;5) reciprocal transcripts and genomic breakpoints in CD30+ cutaneous lymphoproliferations
12. Role of the nucleophosmin (NPM) portion of the non-Hodgkin's lymphoma-associated NPM-anaplastic lymphoma kinase fusion protein in oncogenesis
13. Morphology in Ki-1 (CD30)-positive non-Hodgkin's lymphoma is correlated with clinical features and the presence of a unique chromosomal abnormality, t (2;5) (p23;q35)
14. Major nucleolar proteins shuttle between nucleus and cytoplasm
15. CD30 (+) anaplastic large-cell lymphoma in children: Analysis of 82 patients enrolled in two consecutive studies of the French Society of Pediatric Oncology
16. Ki-1-positive anaplastic large-cell lymphoma can mimic benign dermatoses
17. Bone marrow transplantation for childhood Ki-1 lymphoma
18. Anaplastic large cell Ki-1 lymphoma. Delineation of two morphological types
19. Sarcomatoid variant of anaplastic large-cell Ki-1 lymphoma
20. Isolation and characterization of the human nucleophosmin/B23 (NPM) gene: Identification of the YY1 binding site at the 5′ enhancer region
21. Hypocellular anaplastic large cell lymphoma mimicking inflammatory lesions of lymph nodes
22. t (2;5) positive lymphoma with peripheral blood involvement
23. The interface of Hodgkin's disease and anaplastic large cell lymphoma
24. Ki-1-positive large cell lymphoma. A clinicopathologic study of 41 cases
25. Clinicopathologic, cytogenetic, and molecular studies of 13 Chinese Patients with Ki-1 anaplastic large cell lymphoma. Special emphasis on the tumor response to 13-cis retinoic acid
26. ATIC-ALK: A novel variant ALK gene fusion in anaplastic large cell lymphoma resulting from the recurrent cryptic chromosomal inversion, inv (2) (p23q35)
27. Detection of normal and chimeric nucleophosmin in human cells
28. Differences in clinical behaviour and immunophenotype between primary cutaneous and primary nodal anaplastic large cell lymphoma of T-cell or null cell phenotype
29. Autologous stem cell transplantation for anaplastic large-cell lymphomas: Results of a prospective trial
30. The t (2;5) chromosomal translocation is not a common feature of primary cutaneous CD30+ lymphoproliferative disorders: Comparison with anaplastic large-cell lymphoma of nodal origin
31. Coexpression of epithelial membrane antigen (EMA), Ki-1, and interleukin-2 receptor by anaplastic large cell lymphomas. Diagnostic value in so-called malignant histiocytosis
32. A new subtype of large B-cell lymphoma expressing the ALK kinase and lacking the 2;5 translocation
33. Molecular detection of the (2;5) translocation of non-Hodgkin's lymphoma by reverse transcriptase-polymerase chain reaction
34. Pathobiology of NPM-ALK and variant fusion genes in anaplastic large cell lymphoma and other lymphomas
35. Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia
36. Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease
37. Transcripts of the npm-alk fusion gene in anaplastic large cell lymphoma, Hodgkin's disease, and reactive lymphoid lesions
38. Variable expression of the leucocyte common (CD45) antigen in CD30 (+) anaplastic large cell (ALC) lymphomas. Implication for the differential diagnosis between lymphoid and non-lymphoid malignancies
39. Response of refactory Hodgkin's disease to monoclonal anti-CD30 immunotoxin
40. PG-M1: A new monoclonal antibody directed against a fixative-resistant epitope of the macrophage-associated form of the CD68 molecule
41. CD30 (Ki-1) molecule: A new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy
42. CD30+ anaplastic large-cell lymphoma, null type, with signet-ring appearance
43. Targeted antibodies in the treatment of lymphomas
44. ALK expression defines a distinct group of T/null lymphomas ('ALK lymphomas') with a wide morphological spectrum
45. ALK+ lymphoma: Clinico-pathological findings and outcome
46. Lymphomas expressing ALK fusion protein(s) other than NPM-ALK
47. Primary systemic CD30 (Ki-1)-positive anaplastic large cell lymphoma of the adult: Sequential intensive treatment with the F-MACHOP regimen (+/- radiotherapy) and autologous bone marrow transplantation
48. The expression of TIA-1+ cytolytic-type granules and other cytolytic lymphocyte-associated markers in CD30+ anaplastic large cell lymphomas (ALCL): Correlation with morphology, immunophenotype, ultrastructure, and clinical features
49. Anaplastic large-cell lymphomas of T-cell and null-cell phenotype express cytotoxic molecules
50. Frequent expression of the B-cell-specific activator protein in Reed-Sternberg cell of classical Hodgkin's disease provides further evidence for its B-cell origin
51. Bone marrow involvement in anaplastic large cell lymphoma. Immunohistochemical detection of minimal disease and its prognostic significance
52. Characterization of the transforming activity of p80, a hyperphosphorylated protein in a Ki-1 lymphoma cell line with chromosomal translocation t (2;5)
53. Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma
54. Clinical features of 31 patients with Ki-1 anaplastic large-cell lymphoma
55. Recurrent involvement of 2p23 in inflammatory myofibroblastic tumors
56. A zinc metalloproteinase is responsible for the release of CD30 on human tumor cell lines
57. Anaplastic large-cell lymphomas of B-cell phenotype are anaplastic lymphoma kinase (ALK) negative and belong to the spectrum of diffuse large B-cell lymphomas
58. A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group
59. Regressing atypical histiocytosis: A review and critical appraisal
60. A case of anaplastic lymphoma kinase-positive anaplastic large cell lymphoma presenting with spontaneous splenic rupture: An extremely unusual presentation
61. ALK gene products in anaplastic large cell lymphomas and Hodgkin's disease
62. Absence of anaplastic lymphoma kinase (ALK) and Epstein-Barr virus gene products in primary cutaneous anaplastic large cell lymphoma and lymphomatoid papulosis
63. TRK-fused gene (TFG) is a new partner of ALK in anaplastic large cell lymphoma producing two structurally different TFG-ALK translocations
64. Transformation of the small cell variant Ki-1+ lymphoma to anaplastic large cell lymphoma: Pathologic and clinical features
65. The tyrosine kinase NPM-ALK, associated with anaplastic large cell lymphoma, binds the intracellular domain of the surface receptor CD30 but is not activated by CD30 stimulation
66. Use of an anti-ALK antibody in the characterization of anaplastic large- cell lymphoma of childhood
67. Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system
68. World Health Organization classification of lymphomas: A work in progress
69. Anaplastic large cell lymphoma: The shifting sands of diagnostic hematopathology
70. Ki-1 (CD30) antigen is released by Ki-1 positive tumour-cells in vitro and in vivo. I. Partial characterization of soluble Ki-1 antigen and detection of the antigen cell culture supernatants and in serum by an enzyme-linked immunosorbent assay
71. Primary Ki-1-positive anaplastic large-cell lymphoma: A distinct clinicopathologic entity
72. Anaplastic large cell lymphoma and its morphological variants
73. Primary CD3O+ cutaneous lymphomas (including lymphomatoid papulosis)
74. The t (2;5) in human lymphomas
75. Childhood Ki-1 lymphoma presenting with skin lesions and peripheral lymphadenopathy
76. A novel translocation, t (2;5) (p23;q35), in childhood phagocytic large T-cell lymphoma mimicking malignant histiocytosis
77. Primary and secondary cutaneous Ki-1+ (CD30+) anaplastic large cell lymphomas. Morphologic, immunohistologic, and clinical-characteristics
78. Lymphohistiocytic anaplastic large cell lymphoma stage I: Long-term survival after resection alone
79. A small-cell-predominant variant of primary Ki-1 (CD30)+ T-cell lymphoma
80. Cytotoxic cell antigen expression in anaplastic large cell lymphomas of T- and null-cell type and Hodgkin's disease: Evidence for distinct cellular origin
81. Retrovirus-mediated gene transfer of NPM-ALK causes lymphoid malignancy in mice
82. Most of CD30+ anaplastic large cell lymphoma of B cell type show a somatic mutation in the IgH V region genes
83. The NPM/ALK gene fusion in the pathogenesis of anaplastic large cell lymphoma
84. Aberrant ALK tyrosine kinase signaling. Different cellular lineages, common oncogenic mechanisms
85. Reverse transcriptase polymerase chain reaction for the Ki-1 anaplastic large cell lymphoma-associated t (2;5) translocation in Hodgkin's disease
86. High incidence of the t (2;5) (p23;q35) translocation in anaplastic large cell lymphoma and its lack of detection in Hodgkin's disease. Comparison of cytogenetic analysis, reverse transcriptase-polymerase chain reaction, and P-80 immunostaining
87. A new fusion gene TPM3-ALK in anaplastic large cell lymphoma created by a (1;2) (q25;p23) translocation
88. Expression of the ALK tyrosine kinase gene in neuroblastoma
89. TPM3-ALK and TPM4-ALK oncogenes in inflammatory myofibroblastic tumors
90. Prognostic factors in childhood anaplastic large cell lymphoma: Results of the European Intergroup study
91. Expression of the ALK protein by anaplastic large-cell lymphomas correlates with high proliferative activity
92. The pathogenesis of large cell transformation in cutaneous T-cell lymphoma is not associated with t (2;5) (p23;q35) chromosomal translocation
93. Formation of nucleophosmin/B23 oligomers requires both the amino- and the carboxyl-terminal domains of the protein
94. Anaplastic large cell lymphoma arising in bone: Report of a case of the monomorphic variant with the t (2;5) (p23;q35) translocation
95. Low frequency association of the t (2;5) (p23;q35) chromosomal translocation with CD30+ lymphomas from American and Asian patients. A reverse transcriptase-polymerase chain reaction study
96. Anaplastic large cell malignant lymphoma with extensive eosinophilic or neutrophilic infiltration
97. Inv (2) (p23q35) in anaplastic large-cell lymphoma induces constitutive anaplastic lymphoma kinase (ALK) tyrosine kinase activation by fusion to ATIC, an enzyme involved in purine nucleotide biosynthesis
98. The npm-alk and the atic-alk fusion genes can be detected in non-neoplastic cells
99. Neutrophil-rich, Ki-1-positive anaplastic large-cell malignant lymphoma
100. CD3O-positive large cell lymphomas ('Ki-1 lymphoma') are associated with a chromosomal translocation involving 5q35
101. Nucleolar localization of the nucleophosmin-anaplastic lymphoma kinase is not required for malignant transformation
102. Ki-1 (CD30) anaplastic large-cell lymphoma in children
103. Detection of the t (2;5) (p23;q35) and NPM-ALK fusion in non-Hodgkin's lymphoma by two-color fluorescence in situ hybridization
104. Tropomyosin 4 (TPM4) is fused to ALK by a t(2;19)(p23;p13) in an unusual childhood ALCL with the immunophenotype and functional properties of a natural killer cell malignancy
105. Large cell non-Hodgkin lymphoma of childhood: Analysis of 78 consecutive patients enrolled in 2 consecutive protocols at the Memorial Sloan-Kettering Cancer Center
106. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma
107. ALK, the chromosome 2 gene locus altered by the t (2;5) in non-Hodgkin's lymphoma, encodes a novel neural receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase (LTK)
108. Pediatric lymphomas: Recent advances and commentary on Ki-1-positive anaplastic large-cell lymphomas of childhood
109. Serum levels of the soluble form of CD30 molecule as a tumor marker in CD30+ anaplastic large-cell lymphoma
110. Anaplastic large cell lymphomas presented as bone lesions: A clinicopathologic study of six cases and review of the literature
111. CD30-positive anaplastic large cell lymphoma in childhood: Expression of p80npm/alk and absence of Epstein-Barr virus
112. Role of STAT5 in NPM/ALK-mediated malignant transformation of lymphoid cells
113. Large-cell anaplastic lymphoma-specific translocation (t[2;5] [p23;q35]) in Hodgkin's disease: Indication of a common pathogenesis?
114. Ki-1 (CD30) antigen is regularly expressed by tumor cells of embryonal carcinoma
115. Antitumor activity of anti-CD30 immunotoxin (Ber-H2/saporin) in vitro and in severe combined immunodeficiency disease mice xenografted with human CD30+ anaplastic large-cell lymphoma
116. CD30/Ki-1-positive lymphoproliferative disorders of the skin - Clinicopathologic correlation and statistical analysis of 86 cases: A multicentric study from the European Organization for Research and Treatment of Cancer Cutaneous Lymphoma Project Group
117. A murine xenograft model for human CD30+ anaplastic large cell lymphoma. Successful growth inhibition with an anti-CD30 antibody (HeFi-1)
118. ALK expression as a marker of malignancy. Application to a case of anaplastic large cell lymphoma with huge granulomatous reaction
119. Lymphohistiocytic T-cell lymphoma (anaplastic large cell lymphoma CD30+/Ki-1+ with a high content of reactive histiocytes)
120. Anaplastic large cell lymphoma (CD30+/Ki-1+): Results of a prospective clinico-pathological study of 69 cases
121. Frequent expression of the NPM-ALK chimeric fusion protein in anaplastic large-cell lymphoma, lympho-histiocytic type
122. The monoclonal antibody ALK1 identifies a distinct morphological subtype of anaplastic large cell lymphoma associated with 2p23/ALK rearrangements
123. Detection of anaplastic lymphoma kinase (ALK) and nucleolar protein nucleophosmin (NPM)-ALK proteins in normal and neoplastic cells with the monoclonal antibody ALK1
124. Biochemical detection of novel anaplastic lymphoma kinase proteins in tissue sections of anaplastic large cell lymphoma
125. Immune response to the ALK oncogenic tyrosine kinase in patients with anaplastic large-cell lymphoma
126. Pediatric ALK-positive lymphomas coexpress c-myc
127. BCL-2 is expressed in ALK-negative but not ALK-positive anaplastic large cell lymphoma
128. Successfull treatment strategy for Ki-1 anaplastic large-cell lymphoma of childhood: A prospective analysis of 62 patients enrolled in three consecutive Berlin-Frankfurt-Munster group studies
129. A short pulse chemotherapy is an efficient treatment for anaplastic large cell lymphoma of chilhood: Report of the german-austrian-swiss trial NHL-BFM 90
130. A translocation involving a specific breakpoint (q35) on chromosome 5 is characteristic of anaplastic large cell lymphoma (Ki-1 lymphoma)
131. t (1;2) (q21;p23) and t (2;3) (p23;q21): Two novel variant translocations of the t (2;5) (p23;q35) in anaplastic large cell lymphoma
132. Bone marrow involvement in NPM-ALK-positive lymphoma: Report of two cases
133. Transformation of cutaneous T cell lymphoma to large cell lymphoma. A clinicopathologic and immunologic study
134. Clinicopathologic features and treatment outcome of children with large- cell lymphoma and the t (2;5) (p23;q35)
135. Malignant histiocytosis
136. Production of a monoclonal antibody specific for Hodgkin and Sternberg-Reed cells of Hodgkin's disease and a subset of normal lymphoid cells
137. Cluster report: CD30
138. Diagnosis of t (2;5) (p23;q35)-associated Ki-1 lymphoma with immunohistochemistry
139. Hyperphosphorylation of a novel 80 kDa protein-tyrosine kinase similar to Ltk in a human Ki-1 lymphoma cell line, AMS3
140. Anaplastic large cell lymphomas expressing the novel chimeric protein p80NPM/ALK: A distinct clinicopathologic entity
141. Complex variant translocation t (1;2) with TPM3-ALK fusion due to cryptic ALK gene rearrangement in anaplastic large-cell lymphoma
142. Cutaneous involvement by neutrophil-rich, CD30-positive anaplastic large cell lymphoma mimicking deep pustules
143. Role of phosphatidylinositol 3-kinase-Akt pathway in nucleophosmin/anaplastic lymphoma kinase-mediated lymphomagenesis
144. CD30 antigen, a marker for Hodgkin's lymphoma, is a receptor whose ligand defines an emerging family of cytokines with homology to TNF
145. Primary systemic anaplastic large cell lymphoma (ALCL)
146. Identification of Hodgkin and Reed-Sternberg cells as a unique cell type derived from a newly-detected small-cell population
147. The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: Evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells
148. CD30-positive anaplastic large cell lymphoma: A review of its histopathological, genetic and clinical features
149. The t (2;5) -associated p80 NPM/ALK fusion protein in nodal and cutaneous CD30+ lymphoproliferative disorders
150. Prognostic significance of CD56 expression for ALK-positive and ALK-negative anaplastic large-cell lymphoma of T/null cell phenotype
151. NPM-ALK expression as a diagnostic marker in cutaneous CD30-positive T-cell lymphoproliferative disorders
152. Adverse effects of activated cytotoxic T lymphocytes on the clinical outcome of nodal anaplastic large cell lymphoma
153. ALK expression in extranodal anaplastic large cell lymphoma favours systemic disease with (primary) nodal involvement and a good prognosis and occurs before dissemination
154. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma
155. Primary anaplastic large-cell lymphoma in adults: Clinical presentation, immunophenotype, and outcome
156. Molecular characterization of a new ALK translocation involving moesin (moesin-ALK) in anaplastic large cell lymphoma
157. Further demonstration of the diversity of chromosomal changes involving 2p23 in ALK-positive lymphoma: 2 Cases expressing ALK kinase fused to CLTCL (clathrin chain polypeptide-like)
158. A new variant anaplastic lymphoma kinase (ALK) -fusion protein (ATIC- ALK) in a case of ALK-positive anaplastic large cell lymphoma
159. Anaplastic large cell lymphoma (Ki-1+/CD30+) in childhood
160. Statistical evaluation of diagnostic and prognostic features of CD30+ cutaneous lymphoproliferative disorders: A clinicopathologic study of 65 cases
161. Anaplastic large-cell lymphoma with rapid evolution to leukemic phase
162. Analysis of the t (2;5) (p23;q35) translocation by reverse transcription-polymerase chain reaction in CD30+ anaplastic large-cell lymphomas, in other non-Hodgkin's lymphomas of T-cell phenotype, and in Hodgkin's disease
163. The activated anaplastic lymphoma kinase increases cellular proliferation and oncogene up-regulation in rat 1a fibroblasts
164. Detection of differentially expressed genes in lymphomas using cDNA arrays: Identification of clusterin as a new diagnostic marker for anaplastic large-cell lymphomas
165. EORTC classification for primary cutaneous lymphomas: A proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer
166. Large cell anaplastic lymphoma (ALCL) the UK experience
167. The cryptic inv (2) (p23q35) defines a new molecular genetic subtype of ALK-positive anaplastic large-cell lymphoma
168. Lack of the t (2;5) or other mutations resulting in expression of anaplastic lymphoma kinase catalytic domain in CD30+ primary cutaneous lymphoproliferative disorders and Hodgkin's disease
169. Childhood non-Hodgkin lymphomas in the United Kingdom: Findings from the UK Children's Cancer Study Group
170. Anaplastic large-cell lymphoma: Clinical and prognostic evaluation of 90 adult patients
171. Clinical implications of serum levels of soluble CD30 in 70 adult anaplastic large-cell lymphoma patients